autoimmunity

Enpatoran is an inhibitor of TLR7(IC50 = 11.1 nM) and TLR8(IC50 = 24.1 nM). Enpatoran was found to be inactive against TLR3, TLR4, and TLR9 in vitro and in vivo.

JAK2 STAT3-IN-1 is a GP130 inhibitor with anti-tumor effects and can be used to study inflammation, autoimmunity and cancer.

Anisperimus (LF 15-0195) is an immunosuppressant that enhances activation-induced T-cell death by promoting caspase-8 and caspase-10 activation at the DISC level, and prevents CNS autoimmunity by promoting the development of Foxp3-expressing regulatory CD4 T cells.

Azathioprine (BW 57-322), an immunosuppressive agent, inhibits purine synthesis and GTP-binding protein Rac1 activation.

RVX-297 is a BD2 selective inhibitor of BET bromodomains. RVX-297 preferentially binds to the BD2 domains of the BET bromodomain and Extra Terminal (BET) family of protein.

Compound A, a potent TLR8 agonist, exhibits an EC50 of 0.052 µM and promotes the production of IL-12p40 in human PBMCs with an EC50 of 0.031 µM. This compound is applicable for research in virus resistance, infection resistance, autoimmunity, and tumor studies [1].

Firastotug, an IgG1κ antibody, targets CTLA4, a cytotoxic T lymphocyte-associated protein that serves as a crucial immune checkpoint in autoimmunity and cancer [1].

Syk-IN-4 is a potent, selective, and orally bioavailable inhibitor of SYK, with an IC50 of 0.31 nM, targeting SYK, a potential therapeutic target for autoimmunity and hematological cancers[1].

MOG (92–106), mouse, rat, is a biologically active peptide corresponding to the fragment of amino acids 92 to 106 in myelin oligodendrocyte glycoprotein (MOG) from mice and rats. Mice subjected to MOG (92–106)-induced experimental autoimmune encephalomyelitis show substantial B cell reactivity to secondary myelin antigens. Although this MOG fragment elicits only modest T cell responses, the resultant autoimmunity is profoundly severe. The peptide demonstrates encephalitogenic properties in various species, including SJL mice, DA rats, and rhesus monkeys.

IDO2-IN-1 is a potent, orally active indoleamine 2,3-dioxygenase 2 (IDO2) inhibitor, exhibiting an IC50 value of 112 nM. It is applicable in research related to inflammatory autoimmunity [1].

LTV-1 has the potential for autoimmunity treatment. LTV-1 is a potent lymphoid tyrosine phosphatase (LYP) inhibitor in T cells with an IC50 of 508 nM.

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) is a minor component of the central nervous system myelin that induces potent T-cell and B-cell responses, is highly brain-derived and immunogenic, and causes a relapsing-remitting neurological disease with widespread plaque-like demyelination. [1]

Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist that inhibits T-cell proliferation, offering potential therapeutic applications for kidney transplantation and autoimmune disease research [1].

P2X7-IN-2 TFA (compound 58) is a P2X7 receptor inhibitor with an IC50 value of 0.01 nM for inhibiting IL-Iβ release, used in research on autoimmunity, inflammation, and cardiovascular disease [1].

HG-12-6 is a type II inhibitor of IRAK4, demonstrating preferential binding to unphosphorylated inactive IRAK4 (IC50: 165 nM) and modulating IRAK4 activity in autoimmunity and inflammation.

P2X7-IN-2, a P2X7 receptor inhibitor, effectively suppresses IL-Iβ release, demonstrating an inhibitory concentration (IC50) value of 0.01 nM. This compound is utilized in the study of autoimmunity, inflammation, and cardiovascular disease.

Tifalibep (ABY-039) is a bivalent anti-FcRn antibody mimetic for the study of antibody (IgG)-mediated autoimmunity.